Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial - PubMed (original) (raw)

Randomized Controlled Trial

. 2022 Jan 4;5(1):e2137277.

doi: 10.1001/jamanetworkopen.2021.37277.

Inmaculada López-Hernández 1, Clara Rosso-Fernandez 2, Isabel M Morales 3, Zaira R Palacios-Baena 1, Alicia Hernández-Torres 4, Esperanza Merino de Lucas 5, Laura Escolà-Vergé 6, Elena Bereciartua 7, Elisa García-Vázquez 4, Vicente Pintado 8, Lucía Boix-Palop 9, Clara Natera-Kindelán 10, Luisa Sorlí 11, Nuria Borrell 12, Livia Giner-Oncina 5, Concha Amador-Prous 13, Evelyn Shaw 14, Alfredo Jover-Saenz 15, Jose Molina 16, Rosa M Martínez-Alvarez 17 18, Carlos J Dueñas 19 20, Jorge Calvo-Montes 21, Jose T Silva 22, Miguel A Cárdenes 23, María Lecuona 24, Virginia Pomar 25, Lucía Valiente de Santis 26, Genoveva Yagüe-Guirao 27, María Angeles Lobo-Acosta 2, Vicente Merino-Bohórquez 28, Alvaro Pascual 1, Jesús Rodríguez-Baño 1; REIPI-GEIRAS-FOREST group

Collaborators, Affiliations

Randomized Controlled Trial

Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial

Jesús Sojo-Dorado et al. JAMA Netw Open. 2022.

Abstract

Importance: The consumption of broad-spectrum drugs has increased as a consequence of the spread of multidrug-resistant (MDR) Escherichia coli. Finding alternatives for these infections is critical, for which some neglected drugs may be an option.

Objective: To determine whether fosfomycin is noninferior to ceftriaxone or meropenem in the targeted treatment of bacteremic urinary tract infections (bUTIs) due to MDR E coli.

Design, setting, and participants: This multicenter, randomized, pragmatic, open clinical trial was conducted at 22 Spanish hospitals from June 2014 to December 2018. Eligible participants were adult patients with bacteremic urinary tract infections due to MDR E coli; 161 of 1578 screened patients were randomized and followed up for 60 days. Data were analyzed in May 2021.

Interventions: Patients were randomized 1 to 1 to receive intravenous fosfomycin disodium at 4 g every 6 hours (70 participants) or a comparator (ceftriaxone or meropenem if resistant; 73 participants) with the option to switch to oral fosfomycin trometamol for the fosfomycin group or an active oral drug or parenteral ertapenem for the comparator group after 4 days.

Main outcomes and measures: The primary outcome was clinical and microbiological cure (CMC) 5 to 7 days after finalization of treatment; a noninferiority margin of 7% was considered.

Results: Among 143 patients in the modified intention-to-treat population (median [IQR] age, 72 [62-81] years; 73 [51.0%] women), 48 of 70 patients (68.6%) treated with fosfomycin and 57 of 73 patients (78.1%) treated with comparators reached CMC (risk difference, -9.4 percentage points; 1-sided 95% CI, -21.5 to ∞ percentage points; P = .10). While clinical or microbiological failure occurred among 10 patients (14.3%) treated with fosfomycin and 14 patients (19.7%) treated with comparators (risk difference, -5.4 percentage points; 1-sided 95% CI, -∞ to 4.9; percentage points; P = .19), an increased rate of adverse event-related discontinuations occurred with fosfomycin vs comparators (6 discontinuations [8.5%] vs 0 discontinuations; P = .006). In an exploratory analysis among a subset of 38 patients who underwent rectal colonization studies, patients treated with fosfomycin acquired a new ceftriaxone-resistant or meropenem-resistant gram-negative bacteria at a decreased rate compared with patients treated with comparators (0 of 21 patients vs 4 of 17 patients [23.5%]; 1-sided P = .01).

Conclusions and relevance: This study found that fosfomycin did not demonstrate noninferiority to comparators as targeted treatment of bUTI from MDR E coli; this was due to an increased rate of adverse event-related discontinuations. This finding suggests that fosfomycin may be considered for selected patients with these infections.

Trial registration: ClinicalTrials.gov Identifier: NCT02142751.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Merino de Lucas reported receiving grants from Merck Sharp and Dohme (MSD) outside the submitted work. Dr Pintado reported receiving personal fees from Shionogi, Pfizer, MSD, and Correvio outside the submitted work. Dr Boix-Palop reported receiving travel and congress registration expenses from Pizer and Menarini outside the submitted work. Dr Calvo-Montes reported receiving grants from MSD and Pfizer outside the submitted work. Dr Lecuona reported receiving grants from BioMérieux and Mapfre outside the submitted work. Dr Merino-Bohórquez reported receiving personal fees from AbbVie and Pfizer and grants from Kern Pharma and Amgen outside the submitted work. No other disclosures were reported.

Figures

Figure.

Figure.. Patient Recruitment and Flow Through Study

TOC indicates test of cure.

Comment in

Similar articles

Cited by

References

    1. Rodríguez-Baño J, Pascual A. Clinical significance of extended-spectrum beta-lactamases. Expert Rev Anti Infect Ther. 2008;6(5):671-683. doi:10.1586/14787210.6.5.671 - DOI - PubMed
    1. Holland MS, Nobrega D, Peirano G, Naugler C, Church DL, Pitout JDD. Molecular epidemiology of Escherichia coli causing bloodstream infections in a centralized Canadian region: a population-based surveillance study. Clin Microbiol Infect. 2020;26(11):1554.e1-1554.e8. doi:10.1016/j.cmi.2020.02.019 - DOI - PubMed
    1. Klein EY, Van Boeckel TP, Martinez EM, et al. . Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci U S A. 2018;115(15):E3463-E3470. doi:10.1073/pnas.1717295115 - DOI - PMC - PubMed
    1. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25(4):682-707. doi:10.1128/CMR.05035-11 - DOI - PMC - PubMed
    1. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321-347. doi:10.1128/CMR.00068-15 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources